Previous 10 | Next 10 |
BOTHELL, Wash., March 08, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Barbara Kosacz to its Bo...
BOTHELL, Wash., March 02, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Leen Kawas, Ph.D., President and Chief...
BOTHELL, Wash., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (“ Athira ”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that the underwr...
Shares of Athira Pharma (NASDAQ: ATHA) dropped sharply on Thursday and ended the trading session down by 16.7%. The catalyst for that plunge was the company's announcement on Wednesday evening of the pricing of a new stock offering. Investors were not thrilled with the clinical-stag...
Gainers: Vinco Ventures (BBIG) +312%.ADiTx Therapeutics (ADTX) +90%.Qutoutiao (QTT) +65%.Ideal Power (IPWR) +51%.BiondVax Pharmaceuticals (BVXV) +39%.Celsion (CLSN) +34%.Polar Power (POLA) +33%.Addex Therapeutics (ADXN) +28%.Pioneer Power Solutions (PPSI) +27%.Barnwell Industri...
Cancer Genetics (CGIX) -18%.Obalon Therapeutics (OBLN) -17%.Adamis Pharmaceuticals (ADMP) -17%.Marathon Patent Group (MARA) -11% as Bitcoin crumbles despite good news rolls in.Riot Blockchain (RIOT) -11% as Bitcoin crumbles despite good news rolls in.Foresight Autonomous (...
Athira Pharma (ATHA) has priced its public offering of 4M common shares at $22.50/share, for expected gross proceeds of $90M.Underwriters' over-allotment is an additional 600K shares.Closing date is January 25.Shares down 1% premarket.Previously: Athira Pharma to sell 4M shares of c...
BOTHELL, Wash., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc., (Nasdaq: ATHA) (“ Athira ”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the pricing of i...
The following slide deck was published by Athira Pharma, Inc. in conjunction with this event. For further details see: Athira Pharma (ATHA) Investor Presentation - Slideshow
Athira Pharma ([[ATHA]] -3.7%) trades lower as it announced an underwritten public offering of 4M shares of its common stock.All of the shares in the proposed offering will be sold by Athira.Underwriters granted 30-day option to purchase up to an additional 0.6M shares of its common stoc...
News, Short Squeeze, Breakout and More Instantly...
Reporting of Topline Results Targeted by End of Third Quarter 2024 Results to be presented in oral presentation at Clinical Trials on Alzheimer’s Disease (CTAD) on October 29, 2024, in Madrid, Spain BOTHELL, Wash., July 09, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc (N...
Company to provide overview of Phase 2/3 LIFT-AD clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease (AD); LIFT-AD topline data expected in second half of 2024 Two key opinion leaders will discuss ongoing unmet medical need and LIFT-AD’s primary endpoint...
BOTHELL, Wash., June 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it has completed the first cohort of healthy ...